This study is designed to be a phase II, Open-label, single-arm, single-center study to
evaluate anti-tumor efficacy of TAGRISSO in NSCLC patients in whom T790 mutations are
detected by liquid biopsy using at least one of the samples such as plasma, bronchoalveolar
lavage fluid, and pleural effusion. Approximately 63 patients will be enrolled into the
trial, and expected study duration is 43 months from IRB and Korea: MFDA approval date.
Each subject will continue the study drug (Osimertinib) until disease progression or
manifestation of unacceptable toxicity during the study period. The study drug will be
administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg
daily can be reduced to 40 mg once daily.
A cycle of study treatment is defined as 28 days. Patients will be enrolled for 31 months and
will be followed-up regularly, and duration of follow-up for each patient will be 12 months.
Inclusion Criteria:
1. Age ≥ 20, and patients who understand information about the trial and voluntarily
agree to participate in the trial
2. Histological or cytological confirmation diagnosis of NSCLC and inoperable stage IIIB
or IV at the time of study enrolment
3. Patients with EGFR sensitizing mutation (E19Del, L858R, L861Q, G719X) positive, who
had shown clinical benefits (responders (CR or PR) and SD ≥6 months) from EGFR-TKIs
and had developed progressive disease following those therapy
- Patients who have histories of previous exposure to EGFR-TKIs or other systemic
chemotherapies are permitted (regardless of the order of treatment)
- Treated with at least one of KGFR-TKIs (regardless of treatment with or without
systemic chemotherapies)
- In case the patient previously received any of the treatments including systemic
chemotherapy, radiation therapy, surgery, and hormonal therapy, there should be
at least 2 weeks of time interval between the last day of the previous treatment
and the start of TAGRISSO™, and the remaining toxicity should be ≤ CTCAE grade 1
at the time of starting study treatment (except alopecia and grade 2, prior
platinum-therapy related neuropathy)
4. ECOG performance status 0-2
5. Patients in whom T790 mutations are detected in at least one of the samples including
tumor tissues, BALF (cell-free DNA), plasma (cell-free DNA), and pleural effusion
(cell-free DNA)
6. At least one measurable lesions according to RECIST v 1.1
7. Female with childbearing potential (within 1 year of time interval between last menses
and the date of informed consent) who use appropriate contraception methods and are
not on breast-feeding, and tested negative for pregnancy test or are sure to have a
proof for infertility prior to drug initiation
8. Males willing to use barrier contraception methods during study period (Patients
should inform their sexual partners of the use of the allowed contraception methods.)
9. Patients willing to provide informed consent with date and signature included prior to
all study-specific procedures, samplings and analyse
10. Patients who have proper organ functions as follows:
- ANC ≥ 1500/mm3,
- PLT counts ≥ 100,000/mm3,
- Hb ≥ 9.0g/dL,
- Serum creatinine ≤ upper normal limit,
- AST/ ALT/ ALP ≤ 3 times upper normal limit, Total bilirubin ≤2.0mg/dL (In case of
liver metastasis AST/ ALT/ ALP ≤ 5 times upper normal limit, in case of bone
metastasis, ALP ≤ 5 times upper normal limit)
11. Patients must have a life expectancy ≥ 12 weeks
Exclusion Criteria:
1. Patients who were previously treated with any of the drugs targeting T790M mutation
such as AZD9291 (Osimertinib), HM61713 (Olmutinib), and CO-1686 (Rociletinib)
2. Patients currently receiving medications known to be potent inhibitors of CYP3A4 and
potent inducers of CYP3A4 (at least 1week prior study enrolment)
3. Patients who have preexisting or coexisting malignancies in other parts except for
effectively treated non-melanoma skin cancer, CIS cervical cancer, DCIS breast cancer,
thyroid cancer or malignancies that were effectively treated, have maintained at least
3 years of remission state and can be regarded as completely cured
4. Patients who have severe or unstable medical conditions such as prior or current
clinically significant cardiovascular abnormality in accordance with the
investigator's judgment such as uncontrolled hypertension, heart failure (NYHA
classification ≥3), unstable angina or uncontrolled arrhythmia, and acute myocardial
infarction within 6 months before study enrolment corrected QTcB >450msec in 12 lead
EKG
5. Patients with current or prior interstitial lung disease
6. Patients with current or prior uncontrolled gastrointestinal diseases (e.g., crohn's
disease, ulcerative colitis, chronic diarrhea, malabsorption) that would preclude
adequate absorption of IP.
7. Patients with active hepatitis B (identified by the presence of HBsAg and/or HBV DNA),
active hepatitis C (identified by the presence of HCV RNA), and known human
immunodeficiency virus (HIV)
8. Patients with histories of hypersensitivity to IP or any components of the agent
9. Patients with any of the following genetic predispositions including galactose
intolerance, lactose intolerance, or glucose-galactose malabsorption
10. Patients with symptomatic CNS metastases who are neurologically unstable (Cases with
radiologically and neurologically stable disease after discontinuation of the
administration of corticosteroids and anticonvulsants for at least 4 weeks are
excluded)
11. Patients with uncontrolled infective diseases (Patients who require non-oral
antibiotics injection must be excluded, but they can be included if the diseases are
completely resolved.)
12. Patients who are difficult or unlikely to comply with study procedures, restrictions,
requirements, and follow-up managements according to the investigator's judgment
13. Patients who were administered other study drugs within 30 days before starting the
study treatment (Patients are permitted if they were given any of the drugs including
gefitinib, erlotinib, and afatinib)
14. Patients with any unresolved toxicities from prior therapy greater than Common
Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study
treatment with the exception of alopecia and grade 2, prior platinum-therapy related
neuropathy.
15. Males and females of reproductive potential who are not using an effective method of
birth control and females who are pregnant or breastfeeding or have a positive (urine
or serum) pregnancy test prior to study entry
